Search clinical trials for: bitopertin [RO4917838]

Total 26 results

Hoffmann-La Roche

Completed

A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

Beta-Thalassemia

Italy, Lebanon, Thailand
Disc Medicine, Inc

Enrolling by invitation

Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP

Erythropoietic Protoporphyria

United States, Australia
Hoffmann-La Roche

Completed

A Study of the Relative Bioavailability of Single Dose RO4917838 and the Effect of Food in Healthy Volunteers

Healthy Volunteer

France
Hoffmann-La Roche

Completed

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)

Schizophrenia

United States, China, Italy, Bulgaria, Russian Federation, Japan, Czech Republic
Hoffmann-La Roche

Completed

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)

Obsessive-Compulsive Disorder

United States, Canada
Disc Medicine, Inc

Active, not recruiting

Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP

Erythropoietic Protoporphyria

United States
Hoffmann-La Roche

Completed

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

Schizophrenia

Germany, Spain, Turkey, Canada, United States, Netherlands, Chile, Brazil, Taiwan, Poland, Ukraine, Slovakia, Lithuania, Latvia
Hoffmann-La Roche

Completed

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)

Schizophrenia

Germany, Spain, Turkey, Canada, United States, Netherlands, Chile, Brazil, Taiwan, Poland, Ukraine, Slovakia, Lithuania, Latvia
Hoffmann-La Roche

Completed

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

Schizophrenia

United States, Italy, China, Japan, Russian Federation, Bulgaria, Czech Republic
Hoffmann-La Roche

Completed

A Study of Bitopertin (RO4917838) in Healthy Male Volunteers

Healthy Volunteer

New Zealand
Hoffmann-La Roche

Completed

A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers

Healthy Volunteer

China
Hoffmann-La Roche

Completed

A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838

Healthy Volunteer

France, Russian Federation
Hoffmann-La Roche

Completed

A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838

Healthy Volunteer

France, Russian Federation
Hoffmann-La Roche

Completed

A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy Volunteers

Healthy Volunteer

France
Hoffmann-La Roche

Completed

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

Schizophrenia

United States, Slovakia, Romania, Russian Federation, Ukraine
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia

Steroid-refractory Diamond-Blackfan Anemia (DBA)

United States
Hoffmann-La Roche

Completed

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

Schizophrenia

Finland, Sweden, Korea, Republic of, United States, Colombia, France, Russian Federation, Australia, Hungary, Romania, Mexico, United Kingdom, Argentina, India
Hoffmann-La Roche

Completed

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

Schizophrenia

Korea, Republic of, United States, Hungary, Russian Federation, Argentina, Colombia, India, Australia, Finland, France, Mexico, Romania, Sweden, United Kingdom
Hoffmann-La Roche

Completed

A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

Healthy Volunteer

United States, France
Hoffmann-La Roche

Completed

A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.

Schizophrenia

United States, Poland, Hungary, Russian Federation, Germany, Austria, France, Brazil, Japan, Mexico
Hoffmann-La Roche

Completed

A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder

Schizophrenia

United States
Hoffmann-La Roche

Completed

A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers

Healthy Volunteer

France
Hoffmann-La Roche

Completed

A Study of RO4917838 With Rosuvastatin in Healthy Volunteers

Healthy Volunteer

France
Hoffmann-La Roche

Withdrawn

A Study Exmining the Effect of Multiple Doses of Bitopertin on the Single Dose Pharmacokinetics of Midazolam in Healthy Volunteers.

Healthy Volunteer
Hoffmann-La Roche

Completed

A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study on The Effect of Multiple Dose Carbamazepine on Single Dose Pharmacokinetics of RO4917838 in Healthy Volunteers

Healthy Volunteer

France

3

Subscribe